Document is current

Article History

Received: 9 June 2023

Accepted: 3 October 2023

First Online: 25 October 2023

Declarations

:

: LL received speaker honoraria from AstraZeneca, ReCor Medical and Medtronic. FG is supported by the German Foundation of Heart Research and has received speaker honoraria from Astra-Zeneca. SE received speaker honoraria and/or travel support from Akcea Therapeutics, AstraZeneca, Bayer, Berlin Chemie, Bristol-Myers Squibb, Pfizer, Böhringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Inari medical, Kaneka Pharma, Medtronic, Novartis and Recor. MB is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TTR 219, project number 322900939) and reports personal fees from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, Recor, Servier and Vifor during the conduct of the study. FM is supported by Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219), and Deutsche Herzstiftung. He has received scientific support from Ablative Solutions, Medtronic and ReCor Medical and speaker honoraria/consulting fees from Ablative Solutions, Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, ReCor Medical, Servier, and Terumo. PPN, HAG, BH, PL, SK, AL, and BS report no conflict of interest related to this study.

: The trial was approved by the local ethics committee (ethic committee of the Ärztekammer des Saarlandes) and complied with the Declaration of Helsinki.

: Not applicable.